Wolfgang Miesbach: First Lp(a)‑Specific Therapy in Secondary Prevention?
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn about a recent article by Klaus G Parhofer et al, published in European Heart Journal, adding:
”First Lp(a)‑Specific Therapy in Secondary Prevention?
Pelacarsen Slashes Apheresis in Established CVD.
Elevated lipoprotein(a) [Lp(a)] is a frequent, genetically driven and largely lifestyle‑independent risk factor, present in approximately 20% of the general population and up to 25% of patients with ASCVD – yet we still have no approved Lp(a)‑lowering drug.
In the German Phase 3 Lp(a)FRONTIERS APHERESIS trial (51 patients with established CVD, isolated Lp(a) >60 mg/dL and a median of 44 LA sessions/year), pelacarsen 80 mg SC every 4 weeks almost abolished the need for weekly Lp(a) apheresis:
- normalized LA rate from 0.93 to 0.16 (≈99% reduction in odds of requiring LA),
- 69% complete LA avoidance from week 12–52 vs 0% on placebo,
- and ~72–77% sustained Lp(a) lowering, with mainly mild injection‑site reactions.
Huge congratulations to Dr Klaus Parhofer, Elisabeth Steinhagen-Thiessen and all co‑authors on these impressive data.
Pelacarsen may represent a major step toward a targeted, scalable therapy for genetically elevated Lp(a) in secondary prevention.”
Title: Pelacarsen and lipoprotein(a) apheresis in secondary prevention: the Lp(a)FRONTIERS APHERESIS trial
Authors: Klaus G. Parhofer, Ulrich Julius, Anna Laura Herzog, Thilo Krüger, Julia Weinmann-Menke, Gunnar H. Heine, Hui Cao, Jessica Schorr, Philippe Ferber, Jing Wang, Enrico Cristante, Björn Müller-Edenborn, Anja Vogt, Volker Schettler, Elisabeth Steinhagen-Thiessen
Stay updated on all scientific advances with Hemostasis Today.
-
Jul 7, 2026, 06:19Simone Schoenwaelder: Women Are 25% More Likely to Have Their Stroke Misdiagnosed and Here’s Why
-
Jul 7, 2026, 06:12Dhiraj Bhatia: Extremely Happy to Share Our Review on DNA Nanotechnology in Stroke Repair
-
Jul 7, 2026, 06:04Brian A Beh: An Open Letter to Lisa Murphy Honouring the 30 Years of the Stroke Foundation’s Dedication
-
Jul 7, 2026, 05:55Alan Nurden: A Landmark Review Comparing Hemophilia and Hereditary Angioedema
-
Jul 7, 2026, 05:40Andrew Agwunobi: UConn Health is Proud to Advance Stroke Rehabilitation for Veterans
-
Jul 6, 2026, 22:54Louise St. Germain Bannon: I Wanted to Recognize the Incredible Staff Behind ISTH 2026
-
Jul 6, 2026, 21:46Armghan Ans: UPMC Washington Stroke Program Earns AHA Gold Plus Award for 16th Consecutive Year
-
Jul 6, 2026, 20:31Manik Madaan: Master Transfusion Reactions for USMLE In Less Than 60 Seconds
-
Jul 6, 2026, 19:25Ambreen Kashif: Highlighting the Impact of Temporary Donor Deferrals on Donor Retention